The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer

Hui Yang, Kunlun Wang, Tao Wang, Mengxi Li, Bingxu Li, Shenglei Li, Ling Yuan, Hui Yang, Kunlun Wang, Tao Wang, Mengxi Li, Bingxu Li, Shenglei Li, Ling Yuan

Abstract

Esophageal cancer (EC) is one of the most common cancers with poor survival in the world. Nowadays, a generous number of clinical trials are underway on the use of immunotherapy in EC patients, especially the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. However, only a few patients could benefit from single-agent therapy. Others need combination therapies to enhance the response rate and survival. In this review, we focus on PD-1/PD-L1 inhibitors and its combination options in EC patients. We also summarized the potential predictive biomarkers for PD-1/PD-L1 inhibitors treatment.

Keywords: combination therapy; esophageal cancer; predictive biomarkers; programmed death-1; programmed death-ligand 1.

Copyright © 2020 Yang, Wang, Wang, Li, Li, Li and Yuan.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. (2019) 69:7–34. 10.3322/caac.215512
    1. Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. (2013) 19:5598–606. 10.3748/wjg.v19.i34.5598
    1. Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC, et al. . Interactions between genetic variants and environmental factors affect risk of esophageal adenocarcinoma and barrett's esophagus. Clin Gastroenterol Hepatol. (2018) 16:1598–606. 10.1016/j.cgh.2018.03.007
    1. Kim J, Bowlby R, Mungall AJ, Robertson AG, Odze RD, Cherniack AD, et al. . Integrated genomic characterization of oesophageal carcinoma. Nature. (2017) 541:169–75. 10.1038/nature20805
    1. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. (2014) 15:894–904. 10.1016/S1470-2045(14)70024-5
    1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. (2013) 39:1–8. 10.1016/j.immuni.2013.07.012
    1. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. (2013) 39:61–73. 10.1016/j.immuni.2013.07.005
    1. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. (2015) 348:56–61. 10.1126/science.aaa8172
    1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. (2012) 12:252–64. 10.1038/nrc3239
    1. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. (2017) 18:153. 10.1038/nri.2017.108
    1. Vrána D, Matzenauer M, Neoral C, Aujeský R, Vrba R, Melichar B, et al. . From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci. (2019) 20:13. 10.3390/ijms20010013
    1. Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Lunceford M, et al. . Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. J Clin Oncol. (2018) 36:61–67. 10.1200/JCO.2017.74.9846
    1. Liu M, Guo F. Recent updates on cancer immunotherapy. Precision Clin Med. (2018) 1:65–74. 10.1093/pcmedi/pby011
    1. Alsina M, Moehler M, Lorenzen S. Immunotherapy of esophageal cancer: current status, many trials and innovative strategies. Oncol Res Treat. (2018) 41:266–71. 10.1159/000488120
    1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. (2012) 366:2074–84. 10.1056/NEJMoa1112088
    1. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. (2015) 1:1325–32. 10.1001/jamaoncol.2015.2756
    1. Salama AK, Postow MA, Salama JK. Irradiation and immunotherapy: from concept to the clinic. Cancer. (2016) 122:1659–71. 10.1002/cncr.29889
    1. Kelly RJ, Smith KN, Anagnostou V, Thompson E, Hales RK, Battafarano RJJ, et al. Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. J Clin Oncol. (2019) 37 (Suppl. 4):142 10.1200/JCO.2019.37.4_suppl.142
    1. Lee S, Ahn BC, Park SY, Kim DJ, Lee CG, Cho J, et al. A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). Ann Oncol. (2019) 30(Suppl. 5):mdz266.018 10.1093/annonc/mdz266.018
    1. Uboha NV, Maloney JD, McCarthy D, Deming DA, LoConte NK, Matkowskyj K, et al. Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer. J Clin Oncol. (2019) 37 (Suppl. 15):4041 10.1200/JCO.2019.37.15_suppl.4041
    1. Ende T, Clerq NC, Henegouwen MIB, Gisbertz SS, Meijer SL, Schokker S, et al. A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial. J Clin Oncol. (2019) 37 (Suppl. 15):4045 10.1200/JCO.2019.37.15_suppl.4045
    1. Boonstra JJ, Kok TC, Wijnhoven BP, van Heijl M, van Berge Henegouwen MI, Ten Kate FJ, et al. . Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer. (2011) 11:181. 10.1186/1471-2407-11-181
    1. Zahoor H, Luketich JD, Levy RM, Awais O, Winger DG, Gibson MK, et al. . A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg. (2015) 149:538–47. 10.1016/j.jtcvs.2014.10.044
    1. Drake J, Tauer K, Portnoy D, Weksler B. Adjuvant chemotherapy is associated with improved survival in patients with nodal metastases after neoadjuvant therapy and esophagectomy. J Thorac Dis. (2019) 11:2546–54. 10.21037/jtd.2019.05.66
    1. NCCN Guidelines Version 2 Esophageal and Esophagogastric Junction Cancers. (2019). Available online at:
    1. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, et al. . Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. (2012) 118:2632–40. 10.1002/cncr.26586
    1. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. . INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. (2002) 20:1167–74. 10.1200/JCO.2002.20.5.1167
    1. Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, et al. . Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. (2013) 14:627–37. 10.1016/S1470-2045(13)70136-0
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. . Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. (2018) 379:2342–50. 10.1056/NEJMoa1809697
    1. Gray JE, Villegas AE, Daniel DB, Vicente D, Murakami S, Hui R, et al. Three-year overall survival update from the PACIFIC trial. J Clin Oncol. (2019) 37 (Suppl. 15):8526 10.1200/JCO.2019.37.15_suppl.8526
    1. Mamdani H, Schneider BJ, Abushahin LI, Birdas TJ, Kesler K, Burney H, et al. Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: results from Big Ten Cancer Research Consortium study. J Clin Oncol. (2019) 37 (Suppl. 15):4058 10.1200/JCO.2019.37.15_suppl.4058
    1. Bando H, Kotani D, Tsushima T, Hara H, Kadowaki S, Kato K, et al. TENERGY: multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma. J Clin Oncol. (2019) 37 (Suppl. 15):TPS4141 10.1200/JCO.2019.37.15_suppl.TPS4141
    1. Jing Z, Du D, Zhang N, Dai H, Wang X, Hua Y, et al. Combination of radiation therapy and anti-PD-1 antibody SHR-1210 in treating patients with Esophageal Squamous Cell Cancer. Int J Radiat Oncol Biol Phys. (2018) 102 (Suppl. 3):e31 10.1016/j.ijrobp.2018.07.520
    1. Pang Q, Li X, Zhang W, Qian B, Zhang X, Chen X, et al. Safety and effect of radiation therapy combined with anti-PD-1 antibody SHR-1210 as first- line treatment on patients with intolerable concurrent chemora- diotherapy esophageal cancer: a phase 1b clinical trial. Int J Radiat Oncol Biol Phys. (2018) 102 (Suppl. 3):e39 10.1016/j.ijrobp.2018.07.538
    1. Wanderley CW, Colón DF, Luiz JPM, Oliverira FF, Viacava PR, Leite CA, et al. . Paclitaxel reduces tumor growth by reprogramming tumor- associated macrophages to an M1 profile in a TLR4- dependent manner. Cancer Res. (2018) 78:5891–900. 10.1158/0008-5472.CAN-17-3480
    1. Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, et al. . Trial watch: immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology. (2015) 4:e1008866. 10.1080/2162402X.2015.1008866
    1. Xu N, Yuan XL, Wang BH, Bai YX, Li EX, Li YY, et al. Tislelizumab in combination with chemotherapy for the treatment of Chinese patients (pts) with esophageal squamous cell carcinoma (ESCC): results from one cohort of an ongoing phase 2 study. J Clin Oncol. (2019) 37 (Suppl. 4):14 10.1200/JCO.2019.37.4_suppl.14
    1. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. (2009) 229:12–26. 10.1111/j.1600-065X.2009.00770.x
    1. Lee DH, Kim HR, Keam B, Kato K, Kuboki Y, Vlahovic G, et al. Evaluation of safety and tolerability of durvalumab (D) and tremelimumab (T) in combination with first-line chemotherapy in patients (pts) with esophageal squamous-cell carcinoma. (ESCC). J Clin Oncol. (2019) 37 (Suppl. 4):146 10.1200/JCO.2019.37.4_suppl.146
    1. Zhang B, Qi L, Wang X, Jiang J, Zhang X, Liu Y, et al. Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma. J Clin Oncol. (2019) 37 (Suppl. 15):4033 10.1200/JCO.2019.37.15_suppl.4033
    1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. (2003) 349:2241–52. 10.1056/NEJMra035010
    1. Shah MA. Update on metastatic gastric and esophageal cancers. J Clin Oncol. (2015) 33:1760–9. 10.1200/JCO.2014.60.1799
    1. Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, et al. . Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. (2017) 18:631–9. 10.1016/S1470-2045(17)30181-X
    1. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. . Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. (2019) 20:1506–17. 10.1016/S1470-2045(19)30626-6
    1. Cho BC, Kato K, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in advanced esophageal squamous cell carcinoma (ESCC): the phase III ATTRACTION-3 study. Ann Oncol. (2019) 30 (Suppl. 5):851–934. 10.1093/annonc/mdz394.028
    1. Kato K, Kojima T, Hochhauser D, Bennouna J, Hollebecque A, Lordick F, et al. Pembrolizumab in previously treated metastatic esophageal cancer: longer term follow-up from the phase 2 KEYNOTE-180 Study. J Clin Oncol. (2019) 37 (Suppl. 15):4032 10.1200/JCO.2019.37.15_suppl.4032
    1. Shah MA, Adenis A, Enzinger PC, Kojima T, Muro K, Bennouna J, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. (2019) 37 (Suppl. 15):4010 10.1200/JCO.2019.37.15_suppl.4010
    1. Huang J, Xu BH, Mo HN, Zhang W, Chen X, Wu D, et al. . Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. (2018) 24:1296–304. 10.1158/1078-0432.CCR-17-2439
    1. Huang J, Xu JM, Chen Y, Zhuang W, Zhang YP, Chen ZD, et al. Phase 3 study of camrelizumab vs chemotherapy for locally advanced/metastatic esophageal cancer: the ESCORT Study. In: Oral Presentation at the 15th OESO World Conference for Esophaeal Diseases (2019).
    1. Wang F, Ren C, Zhao Q, Xu N, Shen L, Dai GH, et al. Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockad. J Clin Oncol. (2019) 37 (Suppl. 15):4036 10.1200/JCO.2019.37.15_suppl.4036
    1. FDA Approves Pembrolizumab for Advanced Esophageal Squamous Cell Cancer. Available online at:
    1. He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, et al. . Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. (2016) 107:1193–7. 10.1111/cas.12986
    1. Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, et al. . OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther. (2019) 12:7347–53. 10.2147/OTT.S214211
    1. Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur J Cancer. (2017) 76:167–82. 10.1016/j.ejca.2017.01.011
    1. Chen J, Luo S, Qin S, Cheng Y, Li Z, Fan Y, et al. Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: analysis of the Chinese subgroup in KEYNOTE-181. Anal Oncol. (2019) 30 (Suppl. 5):mdz247.086 10.1093/annonc/mdz247.086
    1. Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. . T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. (2019) 37:318–27. 10.1200/JCO.2018.78.2276
    1. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al. . Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the Phase 2 KEYNOTE-180 study. JAMA Oncol. (2018) 5:546–50. 10.1001/jamaoncol.2018.5441
    1. Xu RH, Wang FH, Shi JH, Feng JF, Shen L, Yang SJ, et al. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced esophageal squamous cell carcinoma: preliminary results of an open-label, multi-cohort, phase Ib/II clinical study. J Clin Oncol. (2018) 36 (Suppl. 4):116 10.1200/JCO.2018.36.4_suppl.116
    1. Noble F, Mellows T, Matthews LHM, Bateman AC, Harris S, Underwood TJ, et al. . Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother. (2016) 65:651–62. 10.1007/s00262-016-1826-5
    1. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. (2016) 4:59. 10.1186/s40425-016-0165-6
    1. Kilic A, Landreneau RJ, Luketich JD, Pennathur A, Schuchert MJ. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res. (2011) 167:207–10. 10.1016/j.jss.2009.08.029
    1. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. (2016)17:e542–51. 10.1016/S1470-2045(16)30406-5
    1. Tumeh PC, Harview CL, Yearley JH, Shintaka P, Taylor EJM, Robert L, et al. . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. (2014) 515:568–71. 10.1038/nature13954
    1. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. . Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. (2016) 6:827–37. 10.1158/-15-1545
    1. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. (2015) 348:124–8. 10.1126/science.aaa1348
    1. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. (2014) 371:2189–99. 10.1056/NEJMoa1406498
    1. Rech AJ, Balli D, Mantero A, Ishwaran H, Nathanson KL, Stager BZ, et al. . Tumor immunity and survival as a function of alternative neopeptides in human cancer. Cancer Immunol Res. (2018) 6:276–87. 10.1158/2326-6066.CIR-17-0559
    1. Zang YS, Dai C, Xu XM, Cai X, Wang G, Wei J, et al. . Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med. (2019) 8:4699–708. 10.1002/cam4.2381
    1. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. . PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. (2015) 372:2509–20. 10.1056/NEJMoa1500596
    1. Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, et al. . Increased Tim-3+ T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients. Cancer Immunol Immunother. (2018) 67:1673–83. 10.1007/s00262-018-2225-x

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner